Disclaimer: This is not financial advice, and investors should conduct their own due diligence before making any investment decisions.
Tiger's Take
With $110 million in funding to date, Carlsmed generated $32M in annual revenue while incurring a $25M net loss, signaling a need for improved financial discipline and a clear path to profitability. I would wait this stock out to see if they can execute the business to profitability in 2026.
S-1 Summary
Carlsmed has filed its S-1 with the SEC, and below is a summary of the S-1 so you don't have to read the whole thing. I did it for you.
Technology: AI-Powered Precision for Spine Surgery
Carlsmed’s aprevo® Technology Platform is redefining spinal fusion surgery through artificial intelligence and patient-specific solutions. The platform leverages predictive analytics and machine learning to create personalized surgical plans and 3D-printed interbody fusion devices tailored to each patient’s unique anatomy. Key components include:
myaprevo® plan: Interactive 3D visualizations for pre-operative planning.
3D-printed implants: Patient-specific interbody devices delivered sterile to the operating room.
Single-use instruments: Designed for...
